Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Int…

October 30, 2010 By Bio-Medicine.Org

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ —
Boehringer Ingelheim Pharmaceuticals, Inc. announced today results
from a Phase Ib study, SOUND-C1, that showed the combination of two
oral hepatitis C virus (HCV) compounds, the protease inhibitor BI
201335 and the polymerase inhibitor BI 207127, with ribavirin
reduced viral load below the lower limit of quantifiable levels in
HCV treatment-naive patients. The regimen did not include
interferon through the first 28 days of treatment. These data are
being presented at the American Association for the Study of Liver
Diseases (AASLD) 2010 Liver Meeting in Boston, MA.

(Poster LB-7) New protease-polymerase inhibitor combination
resulted in 73-100% rapid virological responses without pegylated
interferonIn this randomized open-label trial, 32 treatment-naive
genotype-1 HCV patients received BI 207127 in either 400mg or 600mg
doses three times a day (TID), BI 201335 120mg once daily (QD) and
ribavirin (RBV) (1000/1200mg daily in two doses) for 28 days. All
patients had a rapid and sharp decline in HCV viral load during the
first two days, followed by a slower second phase decline. In the
lower and higher dose groups, 73 and 100% of patients achieved a
rapid virological response (i.e. HCV RNA below lower limit of
quantification after 4 weeks of treatment). One patient experienced
a viral breakthrough (increase by >1 LOG10 from nadir during
treatment) and one other experienced a 0.7 LOG10 increase in viral
load. Both were in the lower dose group of BI 207127 and were
patients with high baseline viral load. On day 29, all patients
were switched to treatment with BI 201335 and PegIFN/RBV for an
additional 44 weeks per the defined study protocol, and will be
followed to evaluate sustained virological response.

“The current standard-of-care, PegIFN/RBV, is challenging for
patients with chronic hepatitis C due to significant side effects
that impact treatment adherence and has suboptimal response

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech